Cue Biopharma, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Cue Biopharma, Inc. on June 22, 2022, covering events occurring on June 16, 2022. The Company is a Delaware corporation with its principal executive offices in Boston, Massachusetts, and its common stock trades on the Nasdaq Capital Market under the symbol "CUE".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
On June 16, 2022, Cameron Gray resigned as a member of the Board of Directors and all committees thereof, effective immediately. The Company stated that Mr. Gray's resignation was not related to any disagreement with the Company regarding its operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the disclosure of the director's departure.
Investor Verification Checklist
- Confirm the current composition of the Board of Directors following Mr. Gray's resignation.
- Verify if a replacement director has been nominated or appointed to fill the vacancy.
- Review subsequent filings for any undisclosed disagreements or related party transactions involving the departing director.